Morning Briefing
Summaries of health policy coverage from major news organizations
FDA Clears A RSV Vaccine For The First Time
The New York Times: RSV Vaccine Approved For Older Adults
The Food and Drug Administration on Wednesday approved GSK’s vaccine for the respiratory syncytial virus, or R.S.V., for adults who are 60 and older, the company said. The vaccine, to be sold as Arexvy, appears to be the first in the world approved for sale to protect older adults from R.S.V., a potentially fatal respiratory illness. (Jewett, 5/3)
The Washington Post: First Vaccine Targeting RSV Wins FDA Approval. More Are Coming
A shot developed by pharmaceutical giant GSK to protect older adults against the respiratory syncytial virus is the first to get a greenlight from the Food and Drug Administration. A Pfizer vaccine is following close behind and is under consideration for older adults and for pregnant people as a maternal vaccination that would protect newborn children. A monoclonal antibody treatment for babies, developed by Sanofi and AstraZeneca to offer vaccine-like protection during the winter RSV season, is also under consideration. (Johnson and Ovalle, 5/3)
Bloomberg: GSK RSV Vaccine Wins US Clearance For Use In Older Adults
The vaccine was authorized for people aged 60 and above by the US Food and Drug Administration, GSK said Wednesday. The UK drugmaker has touted the shot, called Arexvy to sound like RSV, as a potential blockbuster. (Ring, 5/3)
AP: US Approves 1st Vaccine For RSV After Decades Of Attempts
“This is a great first step ... to protect older persons from serious RSV disease,” said Dr. William Schaffner, medical director of the National Foundation for Infectious Diseases, who wasn’t involved with its development. Next, “we’re going to be working our way down the age ladder” for what’s expected to be a string of new protections. (Neergaard, 5/3)
